PureTech Health has the GF Score of 64, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes PureTech Health
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
PureTech Health (LSE:PRTC) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
PureTech Health GF Score Related Terms
LSE:PRTC vs VRTX, REGN, ALNY: GF Score Comparison
For the Biotechnology subindustry, PureTech Health's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's GF Score distribution charts can be found below:
* The bar in red indicates where PureTech Health's GF Score falls into.
PureTech Health (LSE:PRTC) has a GF Score of 64 as of Jun. 30, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on PureTech Health and its competitors. This is 28% above median its historical median of 50.00. Over the past decade, PureTech Health's GF Score has ranged from 7.00 to 80.00.
Is PureTech Health's GF Score too high?
PureTech Health's current GF Score of 64 is 28% above median its 10-year median of 50.00. Over the past 10 years, this metric has ranged from a low of 7.00 to a high of 80.00. Overall, PureTech Health has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's GF Score compare to VRTX and REGN?
PureTech Health's GF Score of 64 can be compared against companies in the Biotechnology industry. Historically, PureTech Health's own GF Score has ranged from 7.00 to 80.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on PureTech Health and its competitors. PureTech Health's current GF Score is 64, which is 28% above median its own 10-year median of 50.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (LSE:PRTC) is currently considered Possible Value Trap. The stock's GF Value™ is £5.27, compared to a current price of £1.34 — trading 74.6% below its estimated fair value. The current GF Score is 64, which is 28% above median its 10-year median of 50.00. PureTech Health's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For PureTech Health (LSE:PRTC), the current GF Score is 64 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (LSE:PRTC) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of £1.34 is trading 74.6% below its estimated GF Value™ of £5.27.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for LSE:PRTC:
GF Score: 64 (28% above median its 10-year median of 50.00)
GF Value™: £5.27 vs. price of £1.34 (74.6% below fair value)
No single metric tells the full story. See the LSE:PRTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
64GF Score
Get the complete analysis for LSE:PRTC
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:PRTC has been successfully added to your 